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Although it has been demonstrated that cAMP pathway affect both adaptive and 
innate cell functions, the role of this pathway in the regulation of T-cell-mediated central 
nervous system (CNS) autoimmune inflammation, such as in experimental autoimmune 
encephalomyelitis (EAE), remains unclear. It is also unclear how cAMP pathway affects 
the function of CD4 T cells in vivo at the site of inflammation. We found that adenylyl 
cyclase activator Forskolin besides inhibition of functions autoimmune CD4 T cells also 
upregulated microRNA (miR)-124 in the CNS during EAE, which is associated with M2 
phenotype of microglia/macrophages. Our study further established that in addition to 
direct influence of cAMP pathway on CD4 T cells, stimulation of this pathway promoted 
macrophage polarization toward M2 leading to indirect inhibition of function of T cells in 
the CNS. We demonstrated that Forskolin together with IL-4 or with Forskolin together 
with IL-4 and IFNγ effectively stimulated M2 phenotype of macrophages indicating high 
potency of this pathway in reprogramming of macrophage polarization in Th2- and 
even in Th1/Th2-mixed inflammatory conditions such as EAE. Mechanistically, Forskolin 
and/or IL-4 activated ERK pathway in macrophages resulting in the upregulation of 
M2-associated molecules miR-124, arginase (Arg)1, and Mannose receptor C-type 1 
(Mrc1), which was reversed by ERK inhibitors. Administration of Forskolin after the onset 
of EAE substantially upregulated M2 markers Arg1, Mrc1, Fizz1, and Ym1 and inhibited 
M1 markers nitric oxide synthetase 2 and CD86 in the CNS during EAE resulting in 
decrease in macrophage/microglia activation, lymphocyte and CD4 T cell infiltration, and 
the recovery from the disease. Forskolin inhibited proliferation and IFNγ production by 
CD4 T cells in the CNS but had rather weak direct effect on proliferation of autoimmune 
T cells in the periphery and in vitro, suggesting prevalence of indirect effect of Forskolin 
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on differentiation and functions of autoimmune CD4 T cells in vivo. Thus, our data indi-
cate that Forskolin has potency to skew balance toward M2 affecting ERK pathway 
in macrophages and indirectly inhibit pathogenic CD4 T  cells in the CNS leading to 
the suppression of autoimmune inflammation. These data may have also implications 
for future therapeutic approaches to inhibit autoimmune Th1 cells at the site of tissue 
inflammation.
Keywords: Th1 cells, neuroinflammation, Forskolin, caMP, microrna-124, macrophage, M2 polarization, erK
inTrODUcTiOn
Various pathways are known to affect differentiation and func-
tion of CD4 T cells in vivo during inflammation associated with 
autoimmunity or infection. One of most common and important 
pathways in the process is cAMP pathway that is known to be 
involved in negative regulation of T cell activation and prolifera-
tion (1). However, more detailed and recent studies demonstrated 
that cAMP-inducing agents Cholera Toxin, 8-bromo-cAMP, and 
FDA-approved drug Forskolin inhibited proliferation of Th1 
but not Th2 effector cells in vitro (2). In addition, it was shown 
that Cholera Toxin-induced expansion rather than inhibition of 
Th17 cells in vivo (3). Pertussis toxin, which was specifically used 
for active induction of central nervous system (CNS) autoimmune 
inflammation, was also shown to activate adenylyl cyclase leading 
to increase in cAMP (4). However, Pertussis toxin stimulated rather 
than inhibited expansion of Th1 cells in vivo leading to develop-
ment of CNS autoimmune inflammation (5). Moreover, selective 
inhibition of cAMP pathway in vivo in CD4 T cells demonstrated 
that cAMP was required for differentiation and proliferation of 
Th1 and Th17 cells but not Th2 and Tregs (6). Thus, exact role of 
cAMP pathway in the modulation of function of effector T cells 
during CNS autoimmune inflammation remains unclear. An 
important factor that could affect functions of T cells in the tis-
sues during inflammation are tissue-resident and blood-derived 
macrophages that are recruited to the sited of inflammation and 
could be also affected by cAMP-inducing agents.
During inflammation, macrophages become activated under 
the influence of T-cell-derived cytokines or pathogens lead-
ing to two or more distinct (polarized) states. Polarization of 
macrophages toward the classic M1 phenotype is induced by 
Th1 cytokines such as IFNγ and the alternative M2 phenotype 
induced by Th2 cytokines such as IL-4 plays an important role in 
regulation of T cells functions during infection and autoimmune 
diseases (7). Recently, it was suggested that macrophages do not 
form stable populations, but rather have distinct phenotypes in 
response to various inflammatory stimuli (e.g., IFNγ vs. IL-4) 
and often form mixed phenotypes (7, 8), which has unpredict-
able impact on functions of T cells at the site of inflammation 
where macrophages serve as antigen-presenting cells. In normal 
Abbreviations: Arg, arginase; ATF, activating transcription factor; BM, bone 
marrow; CNS, central nervous system; CRE, cAMP response elements; EAE, 
experimental autoimmune encephalomyelitis; LFB, luxol fast blue; MOG, myelin 
oligodendrocyte glycoprotein; Mrc, mannose receptor; miR, microRNA; MS, 
multiple sclerosis; NOS, nitric oxide synthetase; REST, RE1-silencing transcription 
factor.
conditions, the CNS has specific microenvironment where 
CNS-resident macrophages (also referred to as microglia) have 
intrinsic M2-like phenotype and express number of M2 markers 
(e.g., Ym1 and IL-4) and specific microRNAs (miRs) (e.g., miR-
124) that promote M2 polarization (9–11). Moreover, CNS has 
internal source of IL-4, which plays critical role in suppression of 
neuroinflammation such as experimental autoimmune encepha-
litis (EAE) (9). M2 macrophages in normal CNS express low level 
of MHC class II and CD86 and do not effectively stimulate T cells.
Similar to human disease multiple sclerosis (MS), EAE is an 
inflammatory disease of the CNS that is initiated by autoimmune 
Th1 and Th17  cells that recognize self-antigen within myelin 
sheath [e.g., myelin oligodendrocyte glycoprotein (MOG)] (12). 
Th1 and Th17 cells produce number of cytokines such as IFNγ, 
TNF, and GM-CSF that mediate M1 polarization of macrophages 
that comprise ~70% of CNS inflammatory lesions and mediate 
most of the damage of neuronal tissue by producing TNF, nitric 
oxide (NO), etc. (7, 12–15). Since CNS has intrinsic M2-skewing 
microenvironment, macrophages in the CNS during EAE and 
other pathologies often exhibit mixed M1/M2 phenotype under 
the influence of CNS-derived IL-4 and Th1-derived IFNγ (16). 
We have previously found that during EAE macrophages exhibit 
dually activated phenotype expressing both M1 and M2 mark-
ers such as CD86 and Ym1 at the same time (9). These results 
were not surprising, since during EAE both M1 (IFNγ) and M2 
(IL-4) cytokines were present in inflamed CNS. Therefore, it is 
important to find new pathways and co-factors that could skew 
macrophage polarization toward M2 in mixed inflammatory 
conditions during EAE.
One of the co-factors that help to skew macrophages toward 
M2 phenotype in the CNS is miR-124 (10). miRs are class of short 
(20–22 nucleotides) non-coding RNAs that regulate many physi-
ological processes including macrophages polarization (11). We 
have previously shown that miR-124 is expressed in microglia in 
normal CNS contributing to M2 phenotype of microglial cells in 
resting state (10). During EAE, expression of miR-124 in activated 
microglia was decreased, while transfection of macrophages 
with miR-124 upregulated M2 markers such as arginase (Arg)1 
and Mannose receptor C-type 1 (Mrc1) and downregulated M1 
markers such as CD86, nitric oxide synthetase (NOS)2, and 
TNF leading to recovery from the disease (10). We also found 
that miR-124 is upregulated in bone marrow (BM)-derived and 
peritoneal macrophages in response to IL-4, but effect of IL-4 
on upregulation of miR-124 was modest (17). Moreover, expres-
sion of miR-124 in microglia in normal CNS was IL-4/IL-13 
independent, while IFNγ pretreated M1 macrophages failed to 
upregulate miR-124 in response to subsequent treatment with 
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IL-4 (17). These data suggest the importance of other pathways 
that may stimulate miR-124 and change balance toward M2 in the 
CNS during inflammation.
Forskolin (coleonol) originate from Indian plant Coleus and 
currently used as food supplement or as a drug for traditional 
oriental medicine and anticancer therapy (18). We found that 
administration of Forskolin during EAE inhibited proliferation 
and IFN-γ production by CD4 T cells in the CNS and upregu-
lated a number of M2-associated molecules miR-124, Arg1, 
Mrc1, Ym1, and Fizz1 and downmodulated M1-associated 
molecules MHC class II, CD86, and NOS2. This indicates very 
potent effect of this drug in the modulation of autoimmune 
CD4 T  cells and macrophage activation/polarization at the 
site of tissue inflammation. To understand mechanisms, we 
were looking for pathways that inhibit pathogenic CD4 T cells, 
enhance action of IL-4 in M2 polarization and upregulation of 
miR-124 during CNS autoimmune inflammation. We found 
that Forskolin did not directly affect CD4 T cells, but promoted 
M2 polarization of macrophages. Further analysis demon-
strated that Forskolin and/or IL-4 activated cAMP-responsive 
element-binding/activating transcription factor (CREB/ATF) 
family proteins that contributed to upregulation of miR-124 
and M2 polarization.
MaTerials anD MeThODs
Mice
C57BL/6 mice were originally purchased from the Jackson 
Laboratory and bred locally at the Laboratory Animal Services 
Center at the Chinese University of Hong Kong. All animal 
procedures were conducted under individual licenses from Hong 
Kong government and approved by animal ethics committee 
form the Chinese University of Hong Kong.
cells
Bone marrow-derived macrophages were grown in DMEM 
media (Gibco) supplemented with 10% FBS (Gibco) and M-CSF 
(R&D; 10  ng/ml) for 5  days as described (10) and used for 
analysis. Peritoneal macrophages were isolated by peritoneal 
lavage and removal of non-adhered cells after 14–16 h of incu-
bation at CO2 incubator (9). Flow cytometry analysis indicated 
96–98% of CD11b+F4/80+ cells in case of BM-derived and 
peritoneal macrophages. For macrophage polarization, the cells 
were treated with IL-4 (50  ng/ml), IFNγ (100  ng/ml), and/or 
Forskolin (30 µM; Sigma) for indicated periods ranging from 2 
to 24 h. The optimal dosage of Forskolin was determined after 
performing dose–response curve (1–100 µM) for the upregula-
tion of miR-124. ERK1/2 inhibitor U0126 was purchased from 
Cell Signaling, and another ERK1/2 PD184352 inhibitor was pur-
chased from Abcam. Inhibitors U0126 and PD184352 were used 
at concentrations of 10 µM and 200 nM, respectively, according 
to the manufacturer’s recommendations. Taurolidin (Sigma) was 
used at the dose of 100  µM. X5050 inhibitor was used at final 
concentration of 100 µM. NRSE inhibitory dsRNA was used at 
concentration of 20  nM as described (19). Primary cultures of 
mouse cortical neurons were performed as described earlier (10).
eae induction
EAE was induced by subcutaneous immunization with 150  µg 
MOG35–55 (American peptide) in 4  mg/ml CFA (Diffco) as 
described earlier (10). Pertussis toxin (Sigma) was injected 
i.p. (150  ng/mouse) on day 0 and day 2 post-immunization. 
Individual animals were assessed daily for symptoms of EAE and 
scored using a scale from 0 to 5 as follows: 0, no disease; 0.5, 
weak tail or mild hind limb ataxia; 1, limp tail and/or hind limb 
ataxia; 2, hind limb paresis; 3, hind limb paralysis; 4, hind and 
fore limb paralysis; 5, death. Forskolin (3 mg/kg) or vehicle (PBS 
with 1% DMSO) was injected i.p. daily starting from disease onset 
(day 14) till the peak of disease (days 21–22). The optimal dosage 
of Forskolin for in vivo administration was selected by titrating 
down reported dosage of 4–5  mg/kg in previously published 
study for anticancer therapy in mouse model (20).
real-time Pcr
For quantitation of various markers and molecules by real-
time RT PCR, total RNA was isolated by Qiagene or MirVana 
(Applied Biosystem) kits from cultured BM-derived, or peri-
toneal macrophages, or form the spinal cords of PBS-perfused 
unmanipulated mice or mice on day 22 following EAE. For 
analysis of miRNA expression, real-time RT-PCR analyses 
were performed using TaqMan miRNA assays for miR-124 
(Applied Biosystems) and relative expressions were calculated 
using the ΔCT method and normalized to uniformly expressed 
snoRNA55 (Applied Biosystems) as we described earlier (10, 21). 
For analysis of mRNA expression for NOS2 (forward primer, 5′-ACC 
CACATCTGGCAGAATGAG-3′; reverse primer, 5′-AGCCATG 
ACCTTTCGCATTAG-3′), Arg1 (forward primer, 5′-CTTGGCT 
TGCTTCGGAACTC-3′; reverse primer, 5′-GGAGAAGGCGTT 
TGCTTAGTTC-3′), and Fizz1 (forward primer, 5′-GCCAGGTC 
CTGGAACCTTTC-3′; reverse primer, 5′-GGAGCAGGGAGAT 
GCAGATGAG-3′), ATF3 forward 5′-AGCATTCACACTCTCC 
AGTTTCTCT-3′, reverse 5′-GGAGAAGACAGAGTGCCTGC-3′, 
IL-1β forward 5′-CTTCCAGGATGAGGACATGAGCAC-3′, 
reverse 5′-TCATCATCCCATGAGTCACAGAGG-3′, IL-6 forward 
5′-CCTTCTTGGGACTGATGCTGGTG-3′, TNF forward 5′-AG 
CCGATGGGTTGTACCTTG-3′ reverse 5′-GTGGGTGAGGA 
GCACGTAGTC-3′, Mrc1 forward 5′-ACCACGGATGACCTGT 
GCTC-3′ reverse 5′-TGGTTCCACACCAGAGCCATC-3′, CCDN1 
forward 5′-GCAGACCATCCGCAAGCATG-3′, reverse 5′-TGG 
AGGGTGGGTTGGAAATGAAC-3′, RE1-silencing transcription 
factor (REST) (for alternative splicing) forward 5′-CGACACATG 
CGGACTCATTC-3′, reverse 5′-GCATGTCGGGTCACTTCA 
TG-3′; Ym1 forward 5′-CCATTGGAGGATGGAAGTTTG-3′, 
reverse 5′-GACCCAGGGTACTGCCAGTC-3′ the relative expres-
sions were calculated using the ΔCT method and normalized to 
the GADPH housekeeping gene (forward primer, 5′-ATGAC 
CACAGTCCATGCCATC-3′; reverse primer, 5′-GAGCTTCCC 
GTTCAGCTCTG-3′), and then relative level of expression was 
calculated in comparison to control conditions as we did earlier (10).
Western Blotting
Western blotting analysis was performed according to standard 
protocol as we reported previously (10). Antibodies for ERK, 
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phospho-ERK, CEBP, phospho-CEBP, CREB, phospho-CREB, 
REST, and β-actin were purchased from Cell Signaling.
Flow cytometry
Mononuclear cells were isolated from the CNS or spleens of mice 
with EAE on day 22 using Percoll gradients as described in our 
previous studies (13, 21). For analysis of microglia, macrophages, 
and lymphocyte populations and macrophage/microglia activa-
tion status, the cells were stained with anti-CD11b-AF480, 
anti-CD86-PE, anti-MHC class II-PE-Cy5 (all from BD 
Bioscience), and F4/80-APC (eBiosceince) or anti-CD45-APC-
Cy7 (BioLegend). FcRs were blocked with a mAb specific for 
mouse FcR (2.4G2; BD Biosciences). CD4 T cells were stained 
for analysis of surface markers with anti-CD4-APC, or anti-
CD4-APC and anti-TCRβ-PE, or anti-CD4-APC and anti-TCR-
Vβ11-PE (all from BD Biosciences). These data were acquired on 
LSR Fortessa cytometer (BD Biosciences) and analyzed using 
FlowJo software (TreeStar Inc.). Absolute numbers of the cells 
were calculated by counting total number of mononuclear cells 
using hemocytometer and by multiplying by the percentages of 
particular populations obtained by flow cytometry.
T-cell and Macrophage Proliferation assay
BrdU incorporation assay was used to assess proliferation of 
BM-derived macrophages or CD4 T cells in vitro or in vivo similar 
as was described in our earlier studies (12). To perform this analy-
sis, we used BrdU kit from BD Biosciences following the manu-
facturer’s instructions. BrdU was injected intraperitoneally (2 mg/
mouse) or added to cultures at final concentration 10  µM 14  h 
before analysis. Macrophages were stained for cell surface markers 
CD11b, F4/80, and for intracellular BrdU-FITC (BD Biosciences) 
and CD11b+F4/80+ gated analyzed for BrdU incorporation by 
three-color flow cytometry. CD4 T cells were stained for cell sur-
face markers CD4 alone, or CD4 and TCR-Vβ11, and intracellular 
BrdU and analyzed by two- or three-color flow cytometry.
cytokine Production by cD4 T cells
For intracellular detection of IFNγ expression, ex vivo isolated 
or cultured CNS or splenic mononuclear cells were activated 
with phorbol myristate acetate (50 ng/ml) and ionomycin (1 µg/
ml; both from Sigma) in the presence of GolgiStop (1 µl/ml, BD 
Biosciences) for 4 h. Cells were washed, immediately stained for 
surface marker anti-CD4-APC, fixed/permeabilized using BD 
intracellular cytokine detection kit, and further stained for intra-
cellular IFNγ using anti-IFNγ-PE (all reagents were purchased 
from BD Biosciences). CD4+ gated cells were analyzed by two-
color flow cytometry.
T-cell recall response
For CD4 T  cell recall response, mice were immunized with 
150 µg MOG35–55 (American peptide) in 4 mg/ml CFA (Diffco) 
as described earlier (10, 22). On day 7 post-immunization, CD4 
T  cells were isolated from draining lymph nodes and spleen 
using negative selection and magnetic beads and incubated in the 
presence of irradiated splenocytes, MOG35–55 peptide (5–10 µg/
ml) or stimulating anti-CD3 (BD Biosciences, clone 145-2C11) 
and anti-CD28 (BD Biosciences, clone 37.51) mAbs as described 
earlier (12). The experiments were performed in the presence of 
30 µM of Forskolin or 0.1% DMSO in media (Control). After 72 h 
of incubation, the dead cells were removed using Ficoll™ gradi-
ent centrifugation, washed and stained for cells surface markers 
CD4 and TCRVβ11, and were analyzed for BrdU incorporation by 
three-color flow cytometry.
immunohistochemistry
Fixed frozen section of lumbar areas of spinal cord were prepared 
and stained with luxol fast blue (LFB, Sigma) as we described 
earlier (10).
statistical analysis
The results are presented as mean ± SE. Unpaired Student’s t-test 
was used to determine significance between two independent 
groups. p Values of less than 0.05 were considered to be signifi-
cant. SigmaPlot program was used for the creation of the graphs 
and performing statistical analysis.
resUlTs
Forskolin Downregulate Mhc class ii and 
cD86 on Microglia and Macrophages in 
the cns during eae resulting in Decrease 
of neuroinflammation and recovery from 
the Disease
Based on literature, we hypothesized that administration of 
Forskolin would lead to activation of cAMP pathway in various 
cell types that might be beneficial for suppression of EAE by 
inhibiting autoimmune CD4 T  cells and/or changing balance 
of macrophage polarization from M1 to M2. We started admin-
istration of Forskolin on the day of onset of the disease, when 
encephalitogenic IFNγ and IL-17 producing Th1 and Th17 cells 
were primed and already migrated into CNS leading to appear-
ance of fist clinical symptoms (Figure 1A, day 14). Administration 
of Forskolin substantially ameliorated the disease leading to 
recovery, while control vehicle-treated group had peak of the 
disease on days 21–22 (Figure 1A). We found that mice treated 
with Forskolin had very low level of demyelination in the spinal 
cord, as determined by LFB staining (Figure  1B). Forskolin-
treated mice had substantially lower level of percentages and 
absolute numbers of CD11b+CD45hi macrophages/activated 
microglia and CD11b−CD45hi lymphocytes in the CNS on day 
22 (Figures 1C,D). Forskolin-treated mice had also diminished 
level of expression of MHC class II and CD86 on CD11b+F4/80+ 
microglia/macrophages in the CNS (Figures 1E,G) but not on 
CD11b+F4/80+ macrophages in the spleen (Figures 1F,G). Thus, 
we found that Forskolin was effective in downmodulation of CNS 
autoimmune inflammation leading to decrease in expression of 
activation marker MHC class II and M1 marker CD86.
Forskolin Upregulated arg1 and inhibited 
nOs2 in the cns during eae by changing 
Balance toward M2
We hypothesized that downregulation of general activation marker 
MHC class II and M1 marker CD86 on microglia/macrophages 
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FigUre 1 | Continued
in the CNS of Forskolin-treated mice with EAE was due to chang-
ing balance toward M2. To further verify this, we investigated the 
expression of additional numbers of M1 (NOS2, TNF), M2 mark-
ers (miR-124, Arg1, Mrc1, Ym-1, Fizz1), and general macrophage 
activation markers (IL-1β, IL-6) in the CNS of control group vs. 
Forskolin-treated group of mice with EAE on day 22. We found 
that miR-124, Arg1, Mrc1, Ym1, and Fizz1 were upregulated in 
Forskolin-treated mice (Figures  2A,B,D–F), while NOS2 was 
FigUre 2 | The effect of Forskolin on skewing balance toward M2 phenotype in the central nervous system during EAE. EAE was induced, and vehicle or Forskolin 
was administrated i.p. on days 14, 15, 16, 17, 19, 20, and 21 post-immunization similarly as for Figure 1. On day 22, mice were perfused with cold PBS, and the 
spinal cords were isolated for RNA isolation and analysis. Expression of M2 markers [microRNA (miR)-124 (a), Arg1 (B), Mrc1 (D), Ym1 (e), and Fizz1 (F)], M1 
markers [NOS2 (c), TNF (i)], and general pro-inflammatory markers [IL-1β (g), IL-6 (h)] was performed by real-time RT-PCR as described in Section “Materials and 
Methods.” In panels (a–i), mean ± SE of triplicate is shown (*p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant).
FigUre 1 | Analysis of the role of Forskolin in the modulation of neuroinflammation and expression of MHC class II and CD86 in the central nervous system 
(CNS) and periphery. EAE was induced and vehicle (PBS with 1% DMSO) or Forskolin were administrated i.p. on days 14, 15, 16, 17, 19, 20, and 21 post-
immunization as described in Section “Materials and Methods.” On day 22, mice were perfused with cold PBS and brains, spinal cords, and spleen were isolated 
for histology (B) and/or flow cytometry analysis (c–h). (a) EAE clinical course (mean ± SE) of total 11–12 individual mice for each group is shown. Injections of 
vehicle or Forskolin are indicated by arrows. (B) Histology analysis of extent of CNS myelination in coronal sections of lumbar area of the spinal cords of 
unmanipulated mice (top image) or mice with EAE on day 22 (bottom images) treated with vehicle (left image) or Forskolin (right image). Extent of myelination was 
assessed in lumbar area of the spinal cord using luxol fast blue (LFB) dye as described in Section “Materials and Methods” (bar: 50 μm; magnification: 400×). 
Quantitative analysis of percentage of myelin-free LFB-negative areas is shown on bar graph on the right. Mean ± SE of six separate images from three individual 
mice is shown (****p < 0.0001). (c,D) The flow cytometry analysis of the CNS mononuclear cells isolated from the mice with EAE on day 22 treated with vehicle 
or Forskolin. The mononuclear cells were isolated from the CNS of mice with EAE, stained for CD11b and CD45, and analyzed by flow cytometry as described in 
Section “Materials and Methods.” The percentages of populations of CD11b+CD45low microglia (left gates), CD11b+CD45hi macrophages (upper right gates), and 
CD11b−CD45hi lymphocytes (lower right gates) are shown. The quantification of the absolute number of macrophages and lymphocytes in the CNS is shown in 
panel (D). (e–h) The flow cytometry analysis of expression of M1-associated markers in macrophages in the CNS (e,g) or spleens (F,h) of mice with EAE on day 
22 treated with Vehicle or Forskolin. Mononuclear cells from CNS (e,g) or spleens (F,h) were stained for CD11b, F4/80, MHC class II, and CD86 and 
CD11b+F4/80+ cells were analyzed for the expression of MHC class II and CD86 by four-color cytometry as described in Section “Materials and Methods.” 
Representative histograms for MHC class II (upper row) and CD86 (bottom row) are shown in panels (e,F). A solid line indicates staining for MHC class II or CD86 
and a dotted line indicates staining for isotype-matched control. A bar indicates percentage of MHC class II or CD86-positive cells. Mean fluorescence intensity 
(MFI) of expression of MHC class II or CD86 is shown at the bottom of each histogram. Quantitative analyses of MHC class II and CD86 expression in 
macrophages in the CNS and spleens are shown in panels (g,h), respectively. In panels (D,g,h), mean ± SE of five individual animals is shown (*p < 0.05; 
**p < 0.01; ***p < 0.001; NS, not significant).
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downregulated (Figure 2C). We did not find statistically signifi-
cant difference for IL-1β, IL6, and TNF (Figures 2G–I). However, 
IL-1β and TNF had trend to be elevated (Figures 2G,I) and IL-6 
had a trend to be decreased (Figure 2H). Notably, we observed the 
dramatic 19-fold upregulation for Arg1 (Figure 2B) and almost 
undetectable level of NOS2 (Figure  2C) in the spinal cord of 
Forskolin-treated mice with EAE. Dramatic upregulation of Arg1 
was in excellent agreement with our in vitro data (Figure 2B). 
Thus, we found that Forskolin skewed the balance toward M2 in 
the CNS during EAE leading to recovery form disease.
Forskolin Decreased Proliferation and 
iFnγ Production by autoimmune cD4  
T cells in the cns, but not in the 
Periphery
Since it was reported that Forskolin could decrease proliferation 
of T cells, we checked the level of proliferation of CD4 T cells 
in the CNS and periphery (spleen) during EAE on day 22. We 
found that that proliferation of CD4 T cells was decreased twofold 
from 20 ±  3 to 9 ±  2% in the CNS of Forskolin-treated mice 
(Figures 3A,E). The level of production of IFNγ by CD4 T cells 
was also decreased in the CNS 1.5-fold, indicating decreased 
level of activation and differentiation of pathogenic Th1  cells 
(Figures  3B,F). This was consisted with 6.3-fold decrease in 
absolute number of infiltrating CD4 T cells in CNS of mice with 
EAE on day 22 (Figure 3G). At the same time, Forskolin did not 
influence the level of proliferation of CD4 T cells in the spleen 
(Figures 3C,H). It was even trend for increase in IFNγ produc-
tion in the spleen of Forskolin-treated mice with EAE on day 22; 
however, it was not statistically significant (Figures 3D,I). We also 
found that during peak of EAE (day 22) mRNA levels for both Th1 
and Th17 cytokines IFNγ and IL-17A were decreased ~8-fold in 
the spinal cords of Forskolin-treated mice when compared with 
vehicle-treated group indicating decrease in activity of both Th1 
and Th17 cells (data not shown). Thus, these data demonstrate 
that administration of Forskolin decreased proliferation and pro-
inflammatory cytokine production by pathogenic CD4 T cells in 
the CNS at the site of inflammation, but not in the periphery.
Forskolin Did not have Direct effect on 
Proliferation of MOg-specific 
autoimmune cD4 T cells
Although we found dramatic effect of Forskolin on EAE disease 
course, macrophage polarization, and proliferation of CD4 T cells 
in the CNS, effect of Forskolin on MOG-specific CD4 T  cells 
could be secondary due to skewing macrophages toward M2, 
which poorly stimulate proliferation and differentiation of Th1 
cells. It was reported that Forskolin directly inhibit proliferation 
of naïve T  cells and T  cell lines stimulated with anti-CD3, but 
the role of Forskolin on proliferation of effector T cells remained 
controversial (23). In our experiments, we started treatment after 
disease onset, when encephalitogenic T cells where already primed 
and become effector CD4 T  cells. These effector CD4 T  cells 
were not inhibited by Forskolin in the spleen and had level of 
proliferation and IFNγ production similar to control group. This 
may indicated that Forskolin had no direct effect on autoimmune 
T cells in the periphery. To address this, we further investigated 
whether Forskolin directly affect proliferation of primed MOG-
specific CD4 T cells in vitro and found that Forskolin had very 
slight trend to decrease proliferation of CD4 T cells form 17 ± 1 
to 15 ± 1% of BrdU-positive cells; however, this difference was 
statistically insignificant (Figures  4A,B; upper figures). When 
we compared extent of proliferation of MOG-specific enriched 
population of CD4+Vβ11+ T cells, the level of proliferation was 
also very similar for control or Forskolin-treated cells compris-
ing 70–80% of CD4+Vβ11+BrdU+ cells (Figures  4A,B; bottom 
figures). Interestingly when we used anti-CD3/CD28 mAbs to 
elicit polyclonal stimulation in the same experiment instead of 
stimulation with MOG antigen, we found that Forskolin induced 
statistically significant 40% decrease in CD4 T cell proliferation 
(Figures 4C,D), as was reported earlier (2, 23). These data dem-
onstrated that in contrast to polyclonally stimulated CD4 T cells, 
primed MOG-specific CD4 T cells were not susceptible to direct 
action of Forskolin. Thus, we demonstrate that Forskolin did not 
have significant direct effect on proliferation of autoimmune 
MOG-specific CD4 T cells in our model.
Forskolin synergize il-4 in Upregulation  
of mir-124 and arg1 even in the Presence 
of iFnγ
Since it was recently demonstrated that cAMP contributed to 
M2 polarization (24, 25), we hypothesized that Forskolin could 
enhance IL-4 in M2 polarization. We analyzed the expression 
of M2-associated molecules miR-124, Arg1, Mrc1, Ym1, Fizz1, 
and M1-associated NOS2 in the presence of Forskolin in M0 
(Control), M2 (IL-4), M1 (IFNγ), and mixed M1/M2 (IL-4 and 
IFNγ) conditions. Experiments demonstrated that combination 
of Forskolin with IL-4 resulted in 3- to 5-fold upregulation of 
miR-124 with average 3.3-fold (Figure 5A, IL4 FSK). However, 
more strikingly we found 3.4-fold upregulation of miR-124 when 
Forskolin was used together with IL-4 and IFNγ (Figure 5A, IL-4 
IFN FSK). At the same time, IL-4 and IFNγ failed to upregulate 
miR-124. This indicates that Forskolin overcome inhibitory 
action of IFNγ in IL-4-induced miR-124 expression, when IL-4 
was used together with IFNγ.
In addition to miR-124, Forskolin substantially enhanced IL-4 
in induction of Arg1 in M2 macrophages (Figure 5B). Forskolin 
synergized expression of Arg1 by 18-fold when compared with 
the action of IL-4 alone (Figure 5B; IL4 and IL4 FSK). Forskolin 
upregulated Arg1 by fivefold in mixed inflammatory conditions 
in the presence of IL-4 and IFNγ (Figure 5B; IFN IL4 and IFN IL4 
FSK). This drug also enhanced expression of M2 marker Mrc1; 
however, it failed to induce it in mixed inflammatory conditions 
(Figure 5C). Finally, Forskolin did not have substantial effect on 
IL-4-induced expression of two other tested M2 markers Ym1 and 
Fizz1 (data not shown).
When we compared expression of M1 markers in IL-4- and 
IFNγ-activated macrophages, we found that Forskolin induced 
low level of NOS2 expression by itself and enhanced induction 
of NOS2 by IFNγ (Figure 5D). Although Arg1 and NOS2 were 
shown to be antagonistic markers, Forskolin induced both in 
mixed inflammatory conditions, but the level of Arg1 was more 
than 10-fold higher than NOS2 (Figures  5B,D, IFN IL4 FSK). 
FigUre 3 | The effect of Forskolin on proliferation and IFNγ production by autoimmune CD4 T cells in the central nervous system (CNS) and periphery during EAE. 
EAE was induced, and vehicle or Forskolin was administrated i.p. on days 14, 15, 16, 17, 19, 20, and 21 post-immunization similarly as for Figure 1. On day 21, 
BrdU was injected i.p. as described in Section “Materials and Methods.” On day 22, mononuclear cells were isolated from CNS or periphery (spleen) as for Figure 1 
and CD4 T cells were analyzed for the expression of surface markers, BrdU incorporation and intracellular IFNγ expression as described in Section “Materials and 
Methods.” (a,c,e,h) To measure CD4 T cell proliferation, BrdU was injected i.p. 14 h before analysis and mononuclear cells were isolated from CNS (a,e) or spleen 
(c,h). The cells were stained for CD4 (x-axis) and BrdU (y-axis) and analyzed with two-color flow cytometry. BrdU incorporation by CD4+ gated cells is shown on 
representative contour-plots (a,c), and statistics is shown in panels (e,h). Percentages of BrdU-positive CD4+ gated cells are shown on the upper left quadrant of 
each contour-plot. Negative controls for BrdU staining are shown at left bottom quadrant of each contour-plot. (B,D,F,i) To measure production of IFNγ by CD4 
T cells, mononuclear cells were isolated from CNS (B,F) or spleen (D,i) and stimulated with PMA/ionomycin in the presence of GolgiStop for 4 h as described in 
Section “Materials and Methods.” Then, the cells were stained for CD4 (x-axis) and IFNγ (y-axis) and analyzed with two-color flow cytometry. IFNγ production by 
CD4+ gated cells is shown on representative contour-plots (B,D), and statistics is shown in panels (F,i). Percentages of IFNγ-positive CD4+ gated cells are shown on 
the upper left quadrant of each contour-plot. Negative controls for IFNγ staining are shown at left bottom quadrant of each contour-plot. (g) Mononuclear cells were 
stained with CD4 and TCRβ and absolute number of CD4+TCRβ+ cells was quantified as for Figure 8. In panels (e–i), mean ± SE of three to five individual mice is 
shown (*p < 0.05; **p < 0.01; NS, not significant).
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FigUre 4 | Analysis of direct effect of Forskolin on the proliferation of myelin oligodendrocyte glycoprotein (MOG)-specific autoimmune CD4 T cells and polyclonally 
stimulated CD4 T cells with anti-CD3/CD28. (a,B) The influence of Forskolin on the proliferation of MOG-specific autoimmune CD4 T cells. Mice were immunized 
with MOG35–55, and on day 7 splenocytes and the cells from draining lymph nodes were isolated. CD4 T cells were purified using magnetic beads and cultured with 
irradiated splenocytes for 72 h without Forskolin for the control sample or with Forskolin (FSK) as described in Section “Materials and Methods.” To measure CD4 
T cell proliferation, BrdU was added 14 h before analysis. The cells were stained for CD4 (x-axis), TCRVβ11, and BrdU (y-axis), and analyzed with three-color flow 
cytometry. Total CD4+ gated cells are shown on upper contour-plots, while CD4+TCRVβ11+ gated cells are shown in bottom contour-plots in panel (a). Percentages 
of BrdU-positive CD4+ gated (top contour-plots) or CD4+TCRVβ11+ gated (bottom contour-plots) CD4 T cells are shown on the upper left quadrant of each 
contour-plot. Negative controls for BrdU staining are shown at left bottom quadrant of each contour-plot. Mean ± SE of four culture wells is shown in panel (B) (NS, 
not significant). (c,D) The influence of Forskolin on the proliferation of polyclonally stimulated CD4 T cells with anti-CD3/CD28. Percentages of BrdU-positive CD4+ 
T cells are show on the upper left quadrant of each contour-plot (c). Negative controls for BrdU staining are shown in a left bottom quadrant of each contour-plot. 
Mean ± SE of four culture wells is shown in panel (B) (***p < 0.001).
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Finally, Forskolin did not affect the expression of other M1 mark-
ers CD86 and TNF (data not shown).
Taken together, these data indicate that Forskolin synergize 
action of IL-4 in induction of miR-124 and Arg1 in the M2-skewing 
condition in the presence of IL-4 and mixed inflammatory condi-
tions (IL-4 with IFNγ) changing balance toward M2.
Forskolin activate erK and synergize 
activation of erK Pathway by il-4
We further investigated mechanism by which Forskolin induce 
expression of M2 markers. It was reported that CEBPβ could 
become phosphorylated by ERK1/2 in response to IFNγ in 
mouse macrophage cell line that play an important role in IFNγ-
inducible gene expression such as NOS2 (26, 27). On the other 
hand, CREB–CEBPβ axis was shown to become activated in LPS-
treated macrophages resulting in expression of number M2 genes 
including Arg1 and Mrc1 while M1 genes remained unaffected 
(28). Thus, the roles of ERK–CEBPβ and CREB–CEBPβ axes 
in M1 vs. M2 remained unclear. We tested whether IL-4 and/or 
Forskolin affect activation CREB, ERK, and CEBPβ by inducing 
their upregulation and/or phosphorylation.
First, we investigated early kinetics of expression level and 
extent of phosphorylation of CREB, ERK, and CEBPβ after 10, 
30, and 60 min of incubation with Forskolin. We found that CREB 
upregulation (Figure 6A; Figure S1 in Supplementary Material) 
and phosphorylation (Figure  6B; Figure S1 in Supplementary 
Material) was detected 10–60  min after incubation with 
Forskolin. We found very modest upregulation of CEBPβ 
(Figure  6C; Figure S1 in Supplementary Material) and only 
slight increase in CEBPβ phosphorylation (Figure 6D; Figure S1 
in Supplementary Material) after 30–60 min of incubation with 
Forskolin. Forskolin induced subtle downregulation (Figure 6E; 
Figure S1 in Supplementary Material) and substantial increase 
FigUre 5 | Effect of Forskolin on the expression microRNA (miR)-124, 
arginase (Arg)1, Mrc1, and nitric oxide synthetase (NOS)2 in bone marrow 
(BM)-derived macrophages at the baseline state (Control), M2 polarizing 
conditions (IL-4), M1 condition (IFNγ), or mixed inflammatory conditions (IL-4 
and IFNγ). BM-derived macrophages were grown for 5 days in the presence 
of M-CSF as described in Section “Materials and Methods” and were treated 
with Forskolin, or IL-4, or IFNγ, or Forskolin/IL-4, or Forskolin/IFNγ, or 
Forskolin/IL-4/IFNγ. After 24 h, the expressions of miR-124 (a), Arg1 (B), 
Mrc1 (c), and NOS2 (D) were analyzed by real-time RT-PCR as described in 
Section “Materials and Methods.” Mean ± SE of four to eight culture wells is 
shown (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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in the level of phosphorylation of ERK1/2, which was detectable 
after 10–60 min of incubation with Forskolin (Figure 6F; Figure 
S1 in Supplementary Material).
Second, we investigated long-term effect of Forskolin and/or 
M1 (IFNγ) and M2 (IL-4) activating stimuli on expression and 
extent of phosphorylation of CREB, ERK, and CEBPβ after 24 h of 
incubation with Forskolin. We found that CREB was upregulated 
by IFNγ and IL-4 (Figure  7A; Figure S1 in Supplementary 
Material), while the highest level of CREB phosphorylation was 
observed in macrophages treated with IL-4 together with Forskolin 
(Figure 7B, IL4/F; Figure S1 in Supplementary Material), which 
was blocked by ERK inhibitor U0126 (Figure  7B, IL4/F/U; 
Figure  S1 in Supplementary Material). Interestingly, we found 
that IL-4 caused the highest level of CREB expression at 24  h 
time-point indicating important role of cAMP in conventional 
IL-4-polarized macrophages (Figure  7A). Most of activating 
stimuli (IFNγ alone, IL-4 alone, or IL-4 with Forskolin, or IFNγ 
with Forskolin) upregulated CEBPβ with little difference in 
extent of phosphorylation of CEBPβ (Figures  7C,D; Figure S1 
in Supplementary Material). ERK inhibitor did not downregu-
late expression of CEBPβ (Figure 7C). ERK expression was not 
influenced by most of activating stimuli while IFN/Forskolin 
and IL-4/Forskolin even decreased it (Figure  7E; Figure S1 in 
Supplementary Material). However, phosphorylation of ERK1/2 
was slightly enhanced by IL-4 or Forskolin, but the highest level of 
ERK phosphorylation was observed when IL-4 was added together 
with Forskolin (Figure 7E; Figure S1 in Supplementary Material). 
In contrast, IFNγ alone did cause substantial phosphorylation of 
ERK, but Forskolin with IFNγ substantially enhanced ERK1/2 
phosphorylation. The ERK inhibitor U0126 blocked phosphoryla-
tion of ERK1/2 caused by IL-4 together with Forskolin, or IFNγ 
with Forskolin (Figure  7E). Thus, we concluded that Forskolin 
enhanced action of IL-4 in phosphorylation of ERK1/2 and 
CREB, but ERK pathway did not play a substantial role in CEBPβ 
phosphorylation.
erK inhibitors Block Upregulation of arg1, 
Mrc1, and mir-124 induced by Forskolin 
with il-4
We found that Forskolin activated ERK1/2 pathway and stimu-
lated expression of M2 markers. We hypothesized that Forskolin 
induced expression of M2 markers and miR-124 via activation 
ERK1/2. However, currently, it is not clear whether ERK1/2 pro-
mote M2 polarization or not. It was reported that ERK1/2 activa-
tion contributed to both M1 and M2 phenotypes (26, 29–32). The 
role of ERK was shown to be important for Th2-mediated allergic 
lung inflammation (33), while the role of miR-124 was also shown 
in our studies to be important for EAE and allergic lung inflam-
mation (10, 17). Therefore, we further investigated the role of 
ERK pathway in upregulation of miR-124, Arg1, Mrc1, and NOS2 
induced by IL-4 together with Forskolin. We found that in the 
presence of ERK inhibitor U0126 the expression of miR-124 fell 
below control level (Table 1, miR-124). In addition to U0126, we 
used another ERK inhibitor P184352 to confirm inhibitory effect 
of U0126. Both ERK inhibitors U0126 and P184352 inhibited 
Arg1 expression by 58 and 98%, respectively (Table 1, Arg1). Both 
inhibitors U0126 and P184352 increased expression of NOS2 by 
fourfold and sevenfold, respectively (Table 1, NOS2). At the same 
time, U0126 decreased expression of Mrc1 by 50%, upregulated 
expression of Ym1 by 25%, and had no effect on Fizz1 expres-
sion (Table 1). Thus, we found that ERK pathway substantially 
contributed to upregulation of miR-124 and Arg1 and downregu-
lation of NOS2 caused by the simultaneous action of IL-4 and 
FigUre 6 | Effect of Forskolin on early activation of downstream signaling pathways CREB, CEBPβ, and ERK1/2. Bone marrow-derived macrophages were grown 
for 5 days in the presence of M-CSF and analyzed as untreated (Control), or were treated with Forskolin (FSK) for 10, 20, or 30 min. Expressions of CREB, CEBPβ, 
and ERK1/2 and their phosphorylated forms (p-CREB, p-CEBPβ, and p-ERK) were analyzed by Western blot as described in Section “Materials and Methods.” 
β-Actin was used as a loading control. (a,c,e) Quantitative analysis of relative expression levels of CREB, CEBPβ, and ERK normalized to β-actin is shown. 
Representative image is shown in Figure S1 in Supplementary Material. (B,D,F) Quantitative analysis of relative expression levels of p-CREB, p-CEBPβ, and p-ERK 
normalized to total CREB, CEBPβ, and ERK1/2, respectively, is shown. Representative image is shown in Figure S1 in Supplementary Material. In panels (a–D), 
mean ± SE of three separate experiments is shown.
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Forskolin. At the same time, we found that Forskolin enhanced 
IFNγ to induce expression of NOS2 (Figure  5D, NOS2). We 
investigated whether ERK pathway contributed to this process as 
it was described earlier for RAW 264.7 cell line (26). We did find 
that ERK pathway partially contributed to IFNγ-inducible NOS2 
expression since U0126 decreased expression of NOS2 by 21% 
(Table 2, NOS2). However, inhibition of ERK pathway resulted 
in twofold increase in TNF expression (Table 2), indicating that 
ERK partially contributed to IFNγ-inducible NOS but not other 
M1 marker TNF. Thus, ERK pathway contributed to upregulation 
of M2 markers miR-124 and Arg1 (Table 1) and partially NOS2 
and downmodulation of TNF (Table 2). These data demonstrated 
FigUre 7 | Effect of Forskolin on activation of downstream signaling pathways CREB, CEBPβ, and ERK1/2 in M0 macrophages (Control), or during M2 (IL-4) vs. M1 
(IFNγ) polarizing conditions. Bone marrow-derived macrophages were grown for 5 days in the presence of M-CSF and were treated with Forskolin, or IL4, or IFNγ, or 
Forskolin/IL4, or Forskolin/IFNγ, or Forskolin/IL4/IFNγ for 24 h as in Figure 1. ERK1/2 inhibitor U0126 was used to block ERK1 and ERK2 phosphorylation (see 
Materials and Methods). Expressions of CREB, CEBPβ, and ERK1/2 and their phosphorylated forms (p-CREB, p-CEBPβ, and p-ERK1/2) were analyzed by Western 
blot as described in Section “Materials and Methods.” β-Actin was used as a loading control. (a,c,e) Quantitative analysis of relative expression levels of CREB, 
CEBPβ, and ERK normalized to β-actin is shown. Representative image is shown in Figure S1 in Supplementary Material. (B,D,F) Quantitative analysis of relative 
expression levels of p-CREB, p-CEBPβ, and p-ERK normalized to total CREB, CEBPβ, and ERK1/2, respectively, is shown. Representative image is shown in Figure 
S1 in Supplementary Material. In panels (a–D), mean ± SE of three separate experiments is shown. Abbreviations: IFN, IFNγ; IL4, IL-4; F, Forskolin; U, U0126.
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importance of ERK pathway in the expression of M2 markers 
miR-124 and Arg1.
erK inhibitor Block Upregulation of arg1, 
Mrc1, and cyclin D2 and Upregulate nOs2 
in il-4 activated BM-Derived 
Macrophages
Since ERK inhibitors inhibited IL-4/Forskolin-induced expres-
sion of miR-124 and Arg1 (Table 1), we hypothesized that ERK 
pathway is important for upregulation of M2 markers in conven-
tional M2 macrophages polarized with IL-4 without Forskolin. 
Our hypothesis was also based on the finding that IL-4 alone but 
not IFNγ alone caused ERK1/2 phosphorylation (Figure  7). It 
was suggested that ERK contribute to M2 phenotype for tumor-
infiltrating macrophages (TIMs) (29, 30), but the role of ERK has 
not be proven to be essential for IL-4-activated macrophages as a 
general concept. We further compared expression of several M2 
markers in IL-4-polarized BM-derived macrophages with and 
without U0126 inhibitor. We found that ERK pathway was critical 
TaBle 2 | Effect of ERK inhibitor U0126 on IFNγ/Forskolin-induced expression 
of NOS2 and TNF.a
Marker Untreated iFnγ FKs iFnγ FsK U0126
NOS2 1.0 ± 0.2 431 ± 20 355 ± 8b
TNF 1.0 ± 0.1 1.2 ± 0.1d 2 ± 0.2c
aBone marrow (BM)-derived macrophages were grown for 5 days in the presence of 
M-CSF and were analyzed as untreated (control) or treated with IFNγ and Forskolin 
without or with ERK inhibitor U0126 for 24 h as for Figure 5. Relative levels compared 
to control are shown for all samples. Mean ± SE of three to six separate wells are 
shown. These data are representative of three separate experiments.
bp < 0.01 when compared to IFNγ/Forskolin (IFNγ FSK) treated cells.
cp < 0.05 when compared to IFNγ/Forskolin (IFNγ FSK) treated cells.
TaBle 1 | Effect of ERK inhibitors U0126 and PD184352 on IL-4/Forskolin-
induced expression of microRNA (miR)-124, Arg1, NOS2, Mrc1, Ym1, and 
Fizz1.a
Marker Untreated il-4 FsK il-4 FKs U0126 il-4 FsK 
PD184352
miR-124 1.0 ± 0.1 2.6 ± 0.2 0.8 ± 0.05b ND
Arg1 1.0 ± 0.2 8,206 ± 442 3,463 ± 74b 180 ± 13c
NOS2 1.0 ± 0.2 9 ± 2 38 ± 7d 65 ± 11d
Mrc1 1.0 ± 0.1 5.6 ± 0.1 2.6 ± 0.1c ND
Ym1 1.0 ± 0.2 15 ± 1 20 ± 1d ND
Fizz1 1.0 ± 0.1 2.7 ± 0.1 2.8 ± 0.2 ND
aBone marrow (BM)-derived macrophages were grown for 5 days in the presence of 
M-CSF and were analyzed as untreated (control) or treated with IL-4 and Forskolin 
without or with ERK inhibitors U0126 or PD184352 for 24 h as for Figure 5. 
Relative levels compared to control are shown for all samples. Mean ± SE of three 
to six separate wells are shown. These data are representative of three separate 
experiments.
bp < 0.001 when compared to IL-4/Forskolin (IL-4 FSK) treated cells.
cp < 0.0001 when compared to IL-4/Forskolin (IL-4 FSK) treated cells.
dp < 0.01 when compared to IL-4/Forskolin (IL-4 FSK) treated cells.
ND, not determined.
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for IL-4-induced upregulation of Arg1, Mrc1 (Figures  8A,B), 
but not Ym1 and Fizz1 (Figures  8C,D). Moreover, Ym1 was 
further upregulated by ERK inhibitor U0126 (Figure  8D). We 
also investigated the level of expression of member of CREB/
ATF family ATF3 as a transcriptional factor that is regulated by 
cAMP and found that ATF3 was upregulated by IL-4, suggesting 
possible involvement of this transcription factor in M2 polariza-
tion (Figure 8E). ERK inhibitor U0126 even further upregulated 
ATF3 in IL-4-treated macrophages (Figure  8E) demonstrating 
that other pathways and/or co-factors were responsible for the 
upregulation of ATF3. Thus, we confirmed ERK pathway was 
important for the upregulation of Arg1 and Mrc1 by IL-4. We also 
found that in addition to CREB, ATF3 might be also involved in 
M2 polarization process but an expression of this factor was ERK 
independent.
It was previously reported that M2 macrophages have 
proliferative capacity in  vivo upon systemic administration 
of IL-4 (34). Since reported proliferation of tissue-resident 
macrophages in peritoneal cavity (35) and microglia in the 
CNS during EAE (14) could be connected with activation 
of ERK pathway, we investigated the level for the expression 
of Cyclin D (CCDN1). CCDN1 plays a central role in the 
regulation of cell division and it is required (but not sufficient 
without other co-factors such as CDK4 and CDK6) for the 
progression from G1 to S phase of cell cycle (36). We found 
that in BM-derived macrophages CCDN1 was expressed at the 
baseline level, which was not surprising since these cells were 
expanded in culture in the presence of M-CSF. However, IL-4 
further upregulated mRNA for Cyclin D1 (Figure 8F, IL4) and 
expression of CCDN1 was completely blocked by ERK inhibitor 
(Figure  8F, IL4 U0126). This indicates that both M-CSF and 
IL-4 contributed to ERK-dependent expression of CCDN1 in 
BM-derived macrophages. We confirmed reported study that 
M-CSF induced ERK phosphorylation (37) in BM-derived 
macrophages (data not shown) suggesting that both IL-4 and 
M-CSF could contribute to the ERK-dependent expression 
of CCDN1. Despite notable upregulation of CCDN1 expres-
sion by IL-4, we did not find very dramatic difference in the 
proliferation of IL-4-treated macrophages in vitro probably due 
to baseline level of M-CSF-driven proliferation of these cells 
(Figures 8G,H). However, ERK inhibitor U0126 did decrease 
proliferation of IL-4-treated BM-derived macrophages by 60%, 
which was consistent with reduced CCDN1 expression in the 
presence of ERK inhibitor (Figures 8G,H). Thus, we found that 
ERK pathway is critical for the expression of Arg1, Mrc1, and 
CCDN1 and downmodulation of NOS2.
erK inhibitor Upregulate expression of 
M1 Marker cD86 in il-4-activated 
Macrophages and nOs2 in iFnγ-activated 
Macrophages
We further investigated and found that ERK inhibitor U0126 
upregulated expression of general activation marker MHC class II 
and M1 marker CD86 in IL-4-treated BM-derived macrophages, 
but not in IFNγ-treated macrophages (Figure 9A; Table 3). In 
addition, ERK inhibitor further upregulated expression of NOS2 
(Figure 9B), but not TNF (Figure 9C). We observed a trend of 
ERK inhibitor upregulating MHC class II in IFNγ-treated mac-
rophages (Figure 9A), but this trend not statistically significant 
(Table  3). Thus, we found that ERK pathway was antagonistic 
for the expression of activation marker MHC class II and M1 
markers CD86 and NOS2.
erK inhibitor Block Upregulation of arg1, 
Mrc1, and cyclin D1 in il-4-activated 
resident Peritoneal Macrophages
We confirmed our results obtained on BM-derived proliferat-
ing macrophages in non-proliferating resident peritoneal 
macrophages. This confirmation was also important to prove 
essential role of ERK in M2 polarization of various types 
of IL-4-stimulated macrophages. Similar to BM-derived 
macrophages, ERK pathway was critical for IL-4-induced 
upregulation of Arg1 and Mrc1, but not Ym1 or Fizz1 
(Figures 10A–D). ATF3 was even further upregulated by ERK 
inhibitor U0126 when compared to BM-derived macrophages 
(Figure 10E). As expected, CCDN1 was not expressed in non-
proliferating peritoneal macrophages, but it was induced by 
IL-4 and completely blocked by ERK inhibitor (Figure 10F). 
FigUre 8 | Analysis of the role of ERK pathway in upregulation of M2 markers and proliferative capacity of bone marrow (BM)-derived macrophages polarized with 
IL-4. BM-derived macrophages were grown for 5 days in the presence of M-CSF and were analyzed as untreated (control) or treated with IL-4, or IL-4 with ERK 
inhibitor U0126 for 24 h as for Figure 2. (a–F) Analysis of M2 marker expression. To assess expression of M2-associated and proliferation markers, RNA was 
isolated and the expression of Arg1, Mrc1, Ym1, Fizz1, ATF3, and CCDN1 (Cyclin D1) was analyzed by real-time RT-PCR as described in Section “Materials and 
Methods.” (g,h) Analysis of macrophage expansion. To assess macrophages proliferation, BrdU was added 14–16 h before analysis to cell cultures, after which the 
cells were stained for surface markers CD11b and F4/80 and intracellular BrdU and analyzed by three-color flow cytometry as described in Section “Materials and 
Methods.” Representative contour-plots for CD11b+F4/80+ gated cells are shown in panel (g). Expression of F4/80 is shown on x-axis and expression of BrdU is 
shown on y-axis. Percentages of BrdU-positive cells are shown on upper right quadrants of each contour-plot. Quantitative analysis for mean ± SE of percentages 
of CD11b+F4/80+BrdU+ cells is shown in panel (h). In panels (a–F,h), mean ± SE of three to five culture wells is shown (**p < 0.01; ***p < 0.001; ****p < 0.0001; 
*****p < 0.00001).
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FigUre 9 | Analysis of the role of ERK pathway in upregulation of M1 markers in bone marrow (BM)-derived macrophages polarized with IFNγ. BM-derived 
macrophages were grown for 5 days in the presence of M-CSF and were analyzed as untreated (control) or treated with IFNγ, or IFNγ with ERK inhibitor U0126 as 
described in Section “Materials and Methods.” (a) Analysis of expression of surface markers MHC class II and CD86 on BM-derived macrophages. To assess 
expression of macrophage activation marker MHC class II and M1 marker CD86, macrophages were stained for CD11b and F4/80, MHC class II and CD86. 
CD11b+F4/80+ gated cells were analyzed for the expression of MHC class II and CD86 by four-color flow cytometry as described in Section “Materials and 
Methods.” A representative histogram for the expression of MHC class II (upper row) and CD86 (bottom row) of CD11b+F4/80+ gated cells is shown. The solid line 
indicated staining for MHC class II or CD86, and the dotted line indicated staining for isotype-matched control. The bar shows percentage of MHC class II or 
CD86-positive cells. The mean fluorescence intensity (MFI) of expression of MHC class II or CD86 is shown at the bottom of each histogram. (B,c) Analysis of 
expression of nitric oxide synthetase (NOS)2 and TNF M1 markers. To assess expression of two other M1-associated markers NOS2 and TNF, RNA was isolated 
and expressions of NOS2 and TNF were analyzed by real-time RT-PCR as described in Section “Materials and Methods.” In panels (B,c), mean ± SE of three to five 
culture wells is shown (***p < 0.001; ****p < 0.0001).
TaBle 3 | Effect of ERK inhibitor U0126 on expression of cell surface markers 
MHC class II and CD86 in M2 (IL-4)- and M1 (IFNγ)-polarized bone marrow (BM)-
derived macrophages.a
Marker Untreated il-4 il-4 U0126 iFnγ iFnγ U0126
MHC class II 9 ± 1 15 ± 1 31 ± 1b 140 ± 7 129 ± 5c
CD86 17 ± 1 15 ± 1 23 ± 1d 38 ± 2 37 ± 1
aBM-derived macrophages were grown for 5 days in the presence of M-CSF and 
were analyzed as untreated (control) or treated with IL-4 or IFNγ without or with ERK 
inhibitor U0126 for 24 h as for Figure 5. After, which macrophages were stained for 
CD11b, F4/80, MHC class II, and CD86. CD11b+F4/80+ gated cells were analyzed for 
the expression of MHC class II and CD86 by four-color flow cytometry as described in 
Section “Materials and Methods.” Mean ± SE of mean fluorescence intensity of MHC 
class II or CD86 on macrophages from four separate wells are shown. These data are 
representative of two separate experiments.
bp < 0.0001 when compared to IL-4 only treated cells (IL-4).
cNot significant difference when compared to IFNγ only treated cells (IFNγ).
dp < 0.01 when compared to IL-4 only treated cells (IL-4).
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We confirmed that IL-4-treated peritoneal macrophages did 
not proliferate in vitro (data not shown), indicating that other 
co-factors (e.g., M-CSF) and other pathways (e.g., Akt) (35) 
are likely to be required for their reported IL-4-driven prolif-
eration in vivo. Thus, these data demonstrate the importance 
of ERK pathway in IL-4-induced expression of Arg1, Mrc1, 
and Cyclin D2 in peritoneal macrophages. This also supports 
our general concept that ERK is essential pathway for M2 
activation.
Forskolin Upregulate mir-124 in  
BM-Derived Macrophages in  
creB/aTF3-Dependent Manner
We have previously found that miR-124 plays an important role 
in M2 macrophage polarization in the CNS and the periphery 
FigUre 10 | Analysis of the role of ERK pathway in the upregulation of M2-associated markers in peritoneal macrophages polarized with IL-4. Peritoneal 
macrophages were isolated as described in Section “Materials and Methods” and were analyzed as untreated (control) or treated with IL-4, or IL-4 with ERK inhibitor 
U0126 for 24 h as for Figure 8. To assess expression of M2-associated and proliferation markers, RNA was isolated and the expression of Arg1, Mrc1, Ym1, Fizz1, 
ATF3, and CCDN1 (Cyclin D1) was analyzed by real-time RT PCR as for Figure 3. In panels (a–F), mean ± SE of three to five culture wells is shown (*p < 0.05; 
**p < 0.01; ***p < 0.001; NS, not significant).
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leading to suppression of EAE (10, 17). Here, we found that 
Forskolin affected miR-124 expression in macrophages. We 
hypothesized that Forskolin induced transcription of precursors 
of miR-124 affecting cAMP-responsive transcription factors. By 
performing in silico analysis of promoter areas of miR-124 pre-
cursor RNAs pre-miR124-1, pre-miR-124-2, and pre-miR-124-3, 
we found the presence of binding sites for several transcription 
factors from cAMP-responsive CREB/ATF family of transcrip-
tion factors in pre-miR124-2 and pre-miR-124-3 promoter areas 
(Figure S2 in Supplementary Material). The most important 
factors from the list of potential regulators of miR-124 (Figure 
S1 in Supplementary Material) were ATF3 and CREB. CREB was 
upregulated by Forskolin (Figure 6A), while ATF3 was upregu-
lated in M2 macrophages by IL-4 (Figures 8E and 10E). It was 
FigUre 11 | Model of changing balance toward M2 by Forskolin in mixed 
inflammatory conditions in the presence of IFNγ and IL4 in the central 
nervous system (CNS) during EAE. Our study demonstrated that IFNγ results 
in the upregulation of M1 marker nitric oxide synthetase (NOS)2 in an 
ERK-independent manner, since IFNγ alone did not result in phosphorylation 
of ERK. However, IFNγ and Forskolin resulted in ERK1/2 phosphorylation, 
contributing to NOS2 expression. IL-4 alone resulted in upregulation of M2 
markers microRNA (miR)-124, arginase (Arg)1, and Mcr1 in an ERK-
dependent manner. Forskolin synergized IL-4 to cause ERK phosphorylation 
and further upregulation of miR-124, Arg1, and Mrc1 in ERK-dependent 
manner. Upregulation by IL-4 and/or Forskolin miR-124 further upregulates 
Arg1 and downregulates NOS2, contributing to skewing macrophages 
toward M2 by Forskolin in the presence of both IL-4 and IFNγ. Thus, 
Forskolin skews balance toward M2 in mixed inflammatory conditions such 
as the CNS autoimmune inflammation during EAE.
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shown to be induced by IFNβ, a known FDA-approved drug (38). 
In addition, ATF3 was recently found to be induced in myeloid 
cells by dimethyl fumarate, another drug used for MS treatment 
(39, 40). ATF3 was also shown to promote anti-inflammatory 
TGFβ signaling and inhibited TNF, which is associated with the 
phenotype of M2 macrophages (41–43). However, when we used 
taurolidin, a known activator of ATF3 (44), we found only modest 
1.5-fold upregulation of miR-124 (Figure S3 in Supplementary 
Material). It was recently shown that CREB-CREBβ axis play a 
major part in induction of expression of M2-associated genes 
Arg1 and Mrc1 (28). Forskolin induced early phosphorylation of 
CEBPβ (Figure 6B) showing activation of CREB–CEBPβ axis in 
macrophages by Forskolin. Thus, we found that Forskolin sub-
stantially upregulated miR-124 in macrophages acting through 
activation of CERB.
resT Does not Play a role in 
Upregulation of mir-124 in Unmanipulated 
or Forskolin-Treated Macrophages
It was shown that miR-124 is highly expressed in neurons due 
to inactivation of transcriptional repressor REST (45). We also 
found that in contrast to neuronal cells, REST (but not the other 
alternative splicing isoform REST4) was highly expressed in 
macrophages on mRNA (Figure S4A in Supplementary Material) 
and protein (Figure S4B in Supplementary Material) levels. 
Importantly, the REST expression was not downregulated by 
Forskolin (Figures S4A,B in Supplementary Material). Thus, REST 
was not downregulated or functionally inhibited by Forskolin. 
Moreover, REST inhibitor X5050 failed to upregulate miR-124 
in unstimulated macrophages (Figure S4C in Supplementary 
Material), while application of REST inhibitory RNA (NRSE) 
resulted in only modest 1.5-fold upregulation of miR-124 
(Figure S4D in Supplementary Material). Thus, we demonstrated 
that Forskolin upregulated miR-124 in macrophages in REST-
independent manner.
DiscUssiOn
This study showed that cAMP pathway is more important to 
modulate function of macrophages rather than T cells during 
EAE. We demonstrated the importance of ERK pathway for 
M2 polarization induced by IL-4 alone or by the synergetic 
action of Forskolin and IL-4 leading to the upregulation of 
miR-124, Arg1, and Mrc1. Forskolin also synergized action of 
IFNγ leading ERK phosphorylation and upregulation of NOS2; 
however, this effect was about 10-fold weaker when compared 
with stimulation of Arg1. In addition, we found that in contrast 
to Forskolin and IL-4, IFNγ alone did not induce ERK phos-
phorylation. We have previously found that miR-124 promote 
expression of Arg1 and Mrc1 and inhibit NOS2 (10, 17) further 
contributing to M2 phenotype. Summarizing all our data, we 
proposed the model in which IL-4 and Forskolin activated 
ERK pathway that promote expression of miR-124, Arg1, and 
Mrc1 (Figure 11). Forskolin alone or in combination with IFNγ 
also promoted NOS2, but this pathway is likely antagonized by 
miR-124, which we found to be critical for M2 phenotype of 
macrophages in the CNS (10) (Figure 11). Our in vitro studies 
were further tested in in vivo in mouse model of autoimmune 
neuroinflammation demonstrating strong therapeutic effect 
of Forskolin and changing balance toward M2 in the CNS in 
mouse model of MS.
The exact role of ERK pathway in macrophage polarization 
remains enigmatic. It was shown that ERK pathway is required for 
macrophage development and M2 skewing of monocytes under 
the action of M-CSF during their growth and differentiation vs. 
M1 phenotype when monocytes are expanded in differentiated 
under the action of GM-CSF (30, 37). However, the role of ERK 
pathway in conventional M2 macrophages that were polarized 
with IL-4 was not investigated in details. Much less is known 
about the activation of ERK pathway in macrophages during 
EAE in mixed inflammatory conditions (IL-4 and IFNγ) and 
possible outcome of activation of this pathway in macrophages 
for the development and resolution of neuroinflammation. Our 
data confirmed that M-CSF-induced ERK phosphorylation, 
but we also demonstrated that IL-4 induced ERK1/2 phos-
phorylation, which was dramatically increased when IL-4 was 
used together with Forskolin. Moreover, we demonstrated that 
ERK1/2 phosphorylation was critical for the expression of 
miR-124, Arg1, Mrc1, and Cyclin D1 in M2 macrophages that 
were polarized by IL-4 with or without Forskolin. In addition 
to M2 activation by IL-4, it was shown in diabetes model that 
TGFβ1 in combination with high level of glucose resulted in 
ERK-dependent upregulation of Arg1, suggesting that ERK 
pathway is involved regulation of Arg1 induced by other M2 
stimuli such as TGFβ1 (46). These data support our findings 
that ERK inhibitor blocked upregulation of Arg1 caused by 
IL-4. In further support of our data with ERK inhibitors, it was 
recently shown that anticancer drug puerarin inhibited ERK 
pathway in TIMs or in IL-4-treated macrophages by skewing 
balance toward M1 (29). Thus, stimulation of ERK pathway in 
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macrophages appeared to be beneficial for M2-skewing and 
downmodulation of Th1/17-driven autoimmune inflammation, 
and vice versa, inhibition of ERK pathway is advantageous for 
M1 skewing in tumor microenvironment and stimulation of 
anticancer immunity. Taken together, modulation of ERK path-
way in macrophages open new possibilities to change M1/M2 
balance in various spectrum of disorders ranging from diabetes 
and cancer to autoimmune disorders and allergy.
ERK pathway is traditionally connected with proliferative 
capacity of the cells; however, its role in proliferation of mac-
rophages is still not clear (47). It was discovered that tissue-
resident M2 macrophages (including CNS-resident microglia 
during EAE) have high-proliferating capacity in  vivo when 
compared with M1 macrophages, but molecular basis for this 
phenomenon remained not known (14, 34). It was shown 
that Forskolin-induced proliferation of thioglycollate-elicited 
macrophages demonstrating important role of CREB in prolif-
eration of macrophages during inflammation (48). Our study 
linked Forskolin with ERK activation and highlighted impor-
tance of ERK pathway in terms of upregulation of expression 
of Cyclin D1 and enhancement of macrophage proliferation by 
IL-4. However, we also found that activation of ERK pathway is 
required but not sufficient to induce and mediate proliferation of 
M2 macrophages. Further studies will elucidate the role of other 
pathways besides ERK in this process. One possible candidate 
is Akt pathway, which is also induced by M-CSF and probably 
IL-4 (35, 48).
ERK pathway was shown to be important in vivo for allergic 
lung inflammation (33). In EAE model, it was recently shown 
that inhibition of ERK resulted in downregulation of GM-CSF, 
a cytokine that promote M1 polarization (49, 50). However, the 
role of ERK is difficult to estimate in vivo during autoimmune 
neuroinflammation since besides macrophages, ERK inhibitors 
also affect CD4 T  cells and dendritic cells (51, 52). Our study 
suggests that stimulation of ERK pathway is beneficial during 
neuroinflammation by changing balance toward M2 in inducing 
miR-124. We previously demonstrated that miR-124 was very 
important in vivo for EAE and allergic lung inflammation models 
promoting M2 polarization while not affecting CD4 T cells and 
dendritic cells (10, 17). Therefore, Forskolin is promising drug 
that stimulate miR-124 in macrophages and suppress autoim-
mune neuroinflammation.
The role of cAMP in M2 polarization was recently high-
lighted in several studies (24, 25, 28). It was also demonstrated 
that treatment of cultured macrophages with 8-bromo-cAMP 
together with IL-4 synergistically activated Arg1 promoter 
(53). We confirmed that cAMP-elevating agent Forskolin also 
synergized IL-4 to induce 18-fold upregulation of Arg1. Our 
study also demonstrated for the first time important role of 
ERK pathway that most likely modulate or serve as a co-factor 
for other known pathways such as CREB–CEBPβ axis and 
STAT6 (28, 53). Currently, the role of cAMP in the modulation 
of ERK activity remains controversial. It was shown that dur-
ing macrophage development cAMP inhibit M-CSF-induced 
ERK expression demonstrating negative role in macrophages 
activation/polarization (54). Our study clearly demonstrate 
that cAMP activate not only CREB but also ERK, which play an 
important role in M2 polarization. In addition to CREB, we also 
found that other members of this family of cAMP-induced tran-
scriptions factors such as ATF3 are upregulated in IL-4-treated 
M2 macrophages. Quite interesting that ATF3 is downregulated 
sevenfold by Forskolin as shown for human macrophages (55). 
Our data also demonstrated that ATF3 was downregulated 
fivefold by Forskolin in mouse BM-derived macrophages (data 
not shown). Thus, CREB and ATF3 are regulated by Forskolin 
in opposite ways. This implies that upregulation of ATF3 in M2 
macrophages treated with ERK inhibitors could happen due to 
compensatory mechanism. In the CNS, ATF3 was upregulated 
early in EAE during preclinical stage, when few infiltrating 
leukocytes were migrating into CNS (56), suggesting that ATF3 
was most likely induced in microglial cells, which become acti-
vated before the onset of EAE (14). Thus, cAMP pathway has 
multiple actions in M2 skewing of macrophages in vitro acting 
through multiple transcriptional factors, which require further 
investigation.
The mechanisms how Forskolin skew macrophages toward 
M2 in vivo during EAE is even complex when compared with 
in vitro models since Forskolin affect many different cell types. 
Macrophages are known to be critical for onset of EAE (57), 
but this disease is also initiated by autoimmune Th1 and Th17 
effector cells (58). Forskolin was shown to inhibit proliferation 
of T cells in vitro during their priming by inhibiting IL-2 signal-
ing (23). In our model, we started administration of Forskolin 
on the day of disease onset (day 14), when Forskolin affected 
already primed effector cells. The role of cAMP pathway is 
more complex in case of effector CD4 T  cells, since there are 
contradictory studies demonstrating either inhibition or stimu-
lation of Th1 and Th17 cells by this pathway (6, 23, 59). Thus, 
there is a possibility that Forskolin also promote expansion of 
Th1 and Th17 cells in vivo during EAE. If this is the case, we 
demonstrated that direct action of Forskolin on macrophages 
could overcome direct effect on T cells. However, what Forskolin 
was doing with encephalitogenic effector CD4 T  cells in  vivo 
remained enigmatic, since Forskolin could affect T  cells indi-
rectly by modulating function of antigen-presenting cells in the 
CNS. To address this conundrum, we performed in vitro experi-
ment investigating direct effect of Forskolin on the proliferation 
of primed MOG-specific enriched population of CD4+Vβ11+ 
T  cells. Our study demonstrated that Forskolin did not have 
significant effect on proliferation of CD4 T cells that were re-
stimulated with MOG peptide. Same results we received when 
we analyzed MOG-specific enriched population of CD4+Vβ11+ 
cells: comparable level of proliferation was observed. On the 
other hand, we confirmed previously published studies that dur-
ing polyclonal stimulation of T cells with anti-CD3, Forskolin 
decreased CD4 T cell proliferation. Our in vitro data indicate 
that MOG-specific autoimmune CD4 T cells were not substan-
tially affected by Forskolin. Thus, we strongly believe that it is 
unlikely that Forskolin directly inhibits effector autoimmune 
CD4 T cells during EAE; rather, Forskolin affect macrophages, 
which result to indirect inhibition of encephalitogenic T cells in 
the CNS. Since Forskolin did not skew balance toward to M2 in 
the periphery (spleen) and did not have direct effect of autoim-
mune CD4 T  cells, this likely explains why proliferation and 
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IFNγ production by CD4 T cells in the spleen was not decreased 
by Forskolin during EAE. We believe that Forskolin affected 
macrophages in the CNS but not in the spleen is due to the 
presence of specific CNS microenvironment such as presence of 
internal source of IL-4 in the CNS (9). Indeed, our data indicate 
that Forskolin skew macrophages toward M2 in the presence of 
IL-4 or IL-4 and IFNγ.
In addition to macrophages, Forskolin is known to affect 
neuronal cells activating BDNF–TrkB–CEBPβ signaling pathway. 
In neurons, CREB–CEBPβ axis increase survival, repair, and 
plasticity (59, 60). Finally, Forskolin may affect oligodendrocytes 
and astrocytes by elevating cAMP and/or ERK1/2 levels and pro-
moting their maturation and differentiation (61–63). We found 
increased LFB staining in the spinal cords of Forskolin-treated 
mice in comparison to within unmanipulated (control) mice; this 
increase could not be attributed to staining artifact. This suggests 
that Forskolin might improve myelination during recovery from 
EAE. Further experiments will establish other cell targets for this 
drug during EAE/MS.
Taken together, our data demonstrated new ERK-dependent 
mechanism of action of Forskolin in skewing of macrophages 
toward M2 in  vitro and in  vivo during EAE. Our study dem-
onstrate an important role of M1/M2 balance in the CNS for 
the regulation of autoimmune inflammation and stimulation 
of pathogenic T  cells, which has potential applications for the 
usage of Forskolin for the therapy of MS and other Th1-mediated 
autoimmune disorders.
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FigUre s1 | Effect of Forskolin on the activation of downstream signaling 
pathways CREB, CEBPβ, and ERK1/2 at a baseline level of BM-derived 
macrophages (Control), or M2 (IL-4) vs. M1 (IFNγ) polarizing conditions. 
BM-derived macrophages were grown for 5 days in the presence of M-CSF 
and were treated with Forskolin, or IL4, or IFNγ, or Forskolin/IL4, or Forskolin/
IFNγ, or Forskolin/IL4/IFNγ for durations of 10, 20, and 30 min or for 24 h. ERK 
inhibitor U0126 was used to block ERK1 and ERK2 phosphorylation (see 
Materials and Methods). Expressions of CREB, CEBPβ, and ERK1/2 and their 
phosphorylated forms (p-CREB, p-CEBPβ, and p-ERK1/2) were analyzed by 
Western blot as described in Section “Materials and Methods.” β-Actin was 
used as a loading control. The same stripped membrane was used to evaluate 
the expression of all proteins including β-actin. These data are representative of 
three separate experiments (abbreviations: I, IFNγ; 4, IL-4; F, Forskolin; U, 
U0126).
FigUre s2 | In silico analysis of the presence of cAMP-response elements 
(CRE) in promoter areas of microRNA (miR)-124 precursor molecule pre-
miR-124-3 and potential transcription factors, which upregulate miR-124 
expression in macrophages. (a) Mapping of cAMP-response elements within 
2,000 bp promoter region upstream of miR-124 precursor molecule pre-
miR-124-3. A list of transcription factors that could potentially bind CRE sites are 
shown on the right. Two selected transcription factors CREB and activating 
transcription factor (ATF)3 are marked in red. Similar CRE sites for binding of 
CREB/ATF family transcriptions factors were also found for pre-miR-124-2 but 
not pre-miR-124-1 precursor molecule (data not shown). (B) Promoter area for 
pre-miR-124-3 with CRE sites are shown for mouse chromosome 2 and human 
chromosome 20.
FigUre s3 | Influence of activating transcription factor (ATF)3 activator taurolidin 
on microRNA (miR)-124 expression in bone marrow (BM)-derived macrophages. 
BM-macrophages were treated with taurolidin for 24 h and miR-124 expression 
was analyzed as described in Section “Materials and Methods.” Mean ± SE of 
triplicate is shown (**p < 0.01).
FigUre s4 | The role of RE1-silencing transcription factor (REST) in the 
expression of microRNA (miR)-124 in macrophages. Bone marrow (BM)-derived 
macrophages were cultured for 5 days as described in Section “Materials and 
Methods.” Then, samples that were untreated (Control), treated with Forskolin 
(a,B), or treated with REST inhibitors (c,D) for the indicated periods were 
analyzed for the expression of REST (a,B) or miR-124 (c,D). (a) Analysis of the 
expression of REST and REST4 in BM-derived macrophages on the mRNA 
level by RT-PCR. BM-derived macrophages were analyzed as untreated 
(Control) or treated with Forskolin (FSK) for 2–4 h. Mouse primary cortical 
neurons (Neu) were used as a control with a low level of REST and REST4 
expressions. Negative control (Neg) was a medium. MW indicate molecular 
weight marker (in bp). GADPH loading control is shown below. (B) Analysis of 
the modulation of the expression of REST in BM-derived macrophages that 
were untreated for 4 or 24 h or treated with Forskolin for 4 or 24 h. Expressions 
of REST were analyzed with Western blot as described in Section “Materials 
and Methods.” Actin was used as a loading control. Representative image is 
shown on the left, quantitative analysis of expression of REST normalized do 
β-actin is shown on the right. Mean ± SE of three separate experiments is 
shown. (c) BM-derived macrophages were incubated with REST inhibitor 
X5050 for 6 or 16 h (overnight), after which the expression of miR-124 was 
assessed by real-time RT-PCR as described in Section “Materials and 
Methods.” (D) BM-derived macrophages were incubated with REST inhibitory 
dsRNA NRSE for 16 h, after which expression of miR-124 was assessed by 
real-time RT-PCR as described in Section “Materials and Methods.” REST 
inhibitory dsRNA NRSE resulted in 1.5-fold upregulation of miR-124. 
Mean ± SE of triplicate is shown (*p < 0.05).
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